Biotech Round-Up: M&As, Financings and Immuno-Oncology

Contributed Opinion
  ()
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. read more >

Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data. read more >

Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal

  ()
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. read more >

Biotech Announces Positive Topline Data in Tourette Syndrome

Research Report
  ()
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. read more >

Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick

Research Report
  ()
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status. read more >

RNAi Therapeutics Developer Reports Positive Amyloidosis Data

Research Report
  ()
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. read more >

CMS Unexpectedly Issues Product Billing Code to Biotech

Research Report
  ()
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm. read more >

Biotech Delivers 'Excellent' Phase 2 Data

Contributed Opinion
  ()
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. read more >

Convergence Will Drive the Ultimate Disruption of Life Sciences

Contributed Opinion
  ()
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night. read more >

Regrouped Biotech's Stock Price Could See Fifteenfold Increase

Research Report
  ()
A recent conference call provided clinical and financial updates. read more >
Expert Investing Ideas

"VIVE's cash as of Q4/17 was $20.7M."

–Jeff Cohen, Ladenburg Thalmann


"PMN is seeking to forge partnerships with big pharmas."

–André Uddin, Mackie Research Capital


Scottsdale Capital Conference

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Medical Device Firm Posts 'Strong Performance' Globally in Q4/17

Research Report
  ()
The company performed strongly in the U.S. and the Asia Pacific region. read more >
Management Q&A: View from the Top

Biotech Advances Treatments for Liver Disease, Pain, Mental Illness

Managment Q&A: View from the Top
  ()
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018. read more >

Price Target on Biotech Is a 700% Potential Increase

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease. read more >

Two Biotechs Earn Analyst's Top Pick Ranking

  ()
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well. read more >
Scottsdale Capital Conference